US62855J1043 - MYGN - 897518 (XNAS)
MYRIAD GENETICS INC Aktie
28,29 USD
Aktuelle Kurse von MYRIAD GENETICS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
MYGN
|
USD
|
19.09.2024 23:02
|
28,29 USD
| 28,47 USD | -0,63 % |
London |
0K3W.L
|
USD
|
19.09.2024 15:50
|
28,63 USD
| 28,47 USD | 0,56 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 2,54 % | 0,35 % | 18,37 % | 30,97 % | 63,34 % | 1,14 % |
Firmenprofil zu MYRIAD GENETICS INC Aktie
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Investierte Fonds
Folgende Fonds haben in MYRIAD GENETICS INC investiert:
Fonds | Vol. in Mio 93,30 | Anteil (%) 0,22 % |
Unternehmensdaten zur MYRIAD GENETICS INC Aktie
Name MYRIAD GENETICS INC
Firma Myriad Genetics, Inc.
Symbol MYGN
Website https://myriad.com
Heimatbörse
NASDAQ
WKN 897518
ISIN US62855J1043
Wertpapierart Aktie
Sektor Healthcare
Branche Medical - Diagnostics & Research
CEO Mr. Paul J. Diaz
Marktkapitalisierung 2 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 2,7 T
Adresse 320 Wakara Way, 84108 Salt Lake City
IPO Datum 1995-10-06
Dividenden von MYRIAD GENETICS INC
Ex-Datum | Dividende pro Aktie |
---|---|
01.07.2009 | 1,75 USD |
15.06.2009 | 1,75 USD |
Aktien-Splits
Datum | Split |
---|---|
26.03.2009 | 2:1 |
12.09.2000 | 2:1 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | MYD.F |
London | 0K3W.L |
NASDAQ | MYGN |
Weitere Aktien
Investoren die MYRIAD GENETICS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024